Exact Therapeutics AS (OSL:EXTX) Cash And Cash Equivalents : kr45.57 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Cash And Cash Equivalents?

Exact Therapeutics AS's quarterly cash and cash equivalents declined from Dec. 2022 (kr68.50 Mil) to Jun. 2023 (kr39.12 Mil) but then increased from Jun. 2023 (kr39.12 Mil) to Dec. 2023 (kr45.57 Mil).

Exact Therapeutics AS's annual cash and cash equivalents declined from Dec. 2021 (kr82.46 Mil) to Dec. 2022 (kr68.50 Mil) and declined from Dec. 2022 (kr68.50 Mil) to Dec. 2023 (kr45.57 Mil).

Exact Therapeutics AS Cash And Cash Equivalents Historical Data

The historical data trend for Exact Therapeutics AS's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS Cash And Cash Equivalents Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

23.24

138.92

82.46

68.50

45.57

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial						82.46	78.81	68.50	39.12	45.57

Exact Therapeutics AS Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Exact Therapeutics AS (OSL:EXTX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Exact Therapeutics AS Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines